{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:48:47Z","timestamp":1787827727273,"version":"build-2784847793"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41571-025-01110-1","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:02:23Z","timestamp":1767607343000},"page":"213-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology"],"prefix":"10.1038","volume":"23","author":[{"given":"Amber","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-4074","authenticated-orcid":false,"given":"Fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Uzunparmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyoung","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-6144","authenticated-orcid":false,"given":"Thuy","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenna R.","family":"Mills Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-0536","authenticated-orcid":false,"given":"Ecaterina Ileana","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Korkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1110_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.21.02767","volume":"40","author":"D Chakravarty","year":"2022","unstructured":"Chakravarty, D. et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J. Clin. Oncol. 40, 1231\u20131258 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR2","doi-asserted-by":"publisher","first-page":"oyaf152","DOI":"10.1093\/oncolo\/oyaf152","volume":"30","author":"NM Shah","year":"2025","unstructured":"Shah, N. M. & Meric-Bernstam, F. The present and future of precision oncology and tumor-agnostic therapeutic approaches. Oncologist 30, oyaf152 (2025).","journal-title":"Oncologist"},{"key":"1110_CR3","doi-asserted-by":"publisher","first-page":"djv098","DOI":"10.1093\/jnci\/djv098","volume":"107","author":"F Meric-Bernstam","year":"2015","unstructured":"Meric-Bernstam, F. et al. A decision support framework for genomically informed investigational cancer therapy. J. Natl Cancer Inst. 107, djv098 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"1110_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins, C. J., Bates, K. M. & Rimm, D. L. HER2 testing: evolution and update for a companion diagnostic assay. Nat. Rev. Clin. Oncol. 22, 408\u2013423 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1110_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.676939","volume":"11","author":"JT Jorgensen","year":"2021","unstructured":"Jorgensen, J. T. et al. A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Front. Oncol. 11, 676939 (2021).","journal-title":"Front. Oncol."},{"key":"1110_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul, J. et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21, 643\u2013650 (2016).","journal-title":"Oncologist"},{"key":"1110_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.path.2017.09.009","volume":"11","author":"HY Wen","year":"2018","unstructured":"Wen, H. Y. & Brogi, E. Lobular carcinoma in situ. Surg. Pathol. Clin. 11, 123\u2013145 (2018).","journal-title":"Surg. Pathol. Clin."},{"key":"1110_CR8","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","volume":"13","author":"MG Davey","year":"2021","unstructured":"Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N. & Lowery, A. J. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers 13, 4455 (2021).","journal-title":"Cancers"},{"key":"1110_CR9","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753\u20133758 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107963","volume":"197","author":"MM Brune","year":"2024","unstructured":"Brune, M. M. et al. MTAP as an emerging biomarker in thoracic malignancies. Lung Cancer 197, 107963 (2024).","journal-title":"Lung Cancer"},{"key":"1110_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","volume":"33","author":"DB Chapel","year":"2020","unstructured":"Chapel, D. B. et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod. Pathol. 33, 245\u2013254 (2020).","journal-title":"Mod. Pathol."},{"key":"1110_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00036","volume":"1","author":"A Johnson","year":"2017","unstructured":"Johnson, A. et al. Clinical use of precision oncology decision support. JCO Precis. Oncol. 1, 1\u201312 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"1110_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-030-16391-4_4","volume":"178","author":"Z Gatalica","year":"2019","unstructured":"Gatalica, Z., Feldman, R., Vranic, S. & Spetzler, D. Immunohistochemistry-enabled precision medicine. Cancer Treat. Res. 178, 111\u2013135 (2019).","journal-title":"Cancer Treat. Res."},{"key":"1110_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s44258-024-00033-3","volume":"2","author":"X Su","year":"2024","unstructured":"Su, X. et al. Challenges and prospects in utilizing technologies for gene fusion analysis in cancer diagnostics. Med-X 2, 14 (2024).","journal-title":"Med-X"},{"key":"1110_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283159","volume":"18","author":"SB Jacobsen","year":"2023","unstructured":"Jacobsen, S. B., Tfelt-Hansen, J., Smerup, M. H., Andersen, J. D. & Morling, N. Comparison of whole transcriptome sequencing of fresh, frozen, and formalin-fixed, paraffin-embedded cardiac tissue. PLoS ONE 18, e0283159 (2023).","journal-title":"PLoS ONE"},{"key":"1110_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep12335","volume":"5","author":"S Graw","year":"2015","unstructured":"Graw, S. et al. Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. Sci. Rep. 5, 12335 (2015).","journal-title":"Sci. Rep."},{"key":"1110_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0643-z","volume":"12","author":"ND Pennock","year":"2019","unstructured":"Pennock, N. D. et al. RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery. BMC Med. Genom. 12, 195 (2019).","journal-title":"BMC Med. Genom."},{"key":"1110_CR18","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","volume":"24","author":"BW Higgs","year":"2018","unstructured":"Higgs, B. W. et al. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin. Cancer Res. 24, 3857\u20133866 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR19","unstructured":"FDA. Nucleic Acid Based Tests. https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/nucleic-acid-based-tests (2025)."},{"key":"1110_CR20","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1200\/JCO.2022.40.16_suppl.3077","volume":"40","author":"J Michuda","year":"2022","unstructured":"Michuda, J. et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J. Clin. Oncol. 40, 3077 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","volume":"28","author":"S Arora","year":"2022","unstructured":"Arora, S. et al. U.S. FDA drug approvals for breast cancer: a decade in review. Clin. Cancer Res. 28, 1072\u20131086 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ygyno.2017.07.003","volume":"146","author":"CM Cosgrove","year":"2017","unstructured":"Cosgrove, C. M. et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol. Oncol. 146, 588\u2013595 (2017).","journal-title":"Gynecol. Oncol."},{"key":"1110_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/gcc.23014","volume":"61","author":"JC Haan","year":"2022","unstructured":"Haan, J. C. et al. MammaPrint and blueprint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. Genes Chromosomes Cancer 61, 148\u2013160 (2022).","journal-title":"Genes Chromosomes Cancer"},{"key":"1110_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102964","volume":"151","author":"NR Latha","year":"2020","unstructured":"Latha, N. R. et al. Gene expression signatures: a tool for analysis of breast cancer prognosis and therapy. Crit. Rev. Oncol. Hematol. 151, 102964 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1110_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801","volume":"75","author":"A Prat","year":"2022","unstructured":"Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine 75, 103801 (2022).","journal-title":"eBioMedicine"},{"key":"1110_CR27","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446\u20131452 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"1110_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","volume":"117","author":"DE Spratt","year":"2023","unstructured":"Spratt, D. E. et al. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology\/RTOG 0126 randomized phase 3 trial. Int. J. Radiat. Oncol. Biol. Phys. 117, 370\u2013377 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1110_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari, F., Minutolo, F. & Orciuolo, E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J. Hematol. Oncol. 11, 84 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1110_CR30","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","volume":"18","author":"GK Lambert","year":"2013","unstructured":"Lambert, G. K., Duhme-Klair, A. K., Morgan, T. & Ramjee, M. K. The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov. Today 18, 992\u20131000 (2013).","journal-title":"Drug Discov. Today"},{"key":"1110_CR31","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/cncr.32649","volume":"126","author":"M Nikanjam","year":"2020","unstructured":"Nikanjam, M., Okamura, R., Barkauskas, D. A. & Kurzrock, R. Targeting fusions for improved outcomes in oncology treatment. Cancer 126, 1315\u20131321 (2020).","journal-title":"Cancer"},{"key":"1110_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr.","year":"2020","unstructured":"Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol. Res. 152, 104609 (2020).","journal-title":"Pharmacol. Res."},{"key":"1110_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/ijms25020849","volume":"25","author":"KS Shan","year":"2024","unstructured":"Shan, K. S. et al. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. Int. J. Mol. Sci. 25, 849 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1110_CR34","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/s41388-023-02712-8","volume":"42","author":"S Zhao","year":"2023","unstructured":"Zhao, S., Li, J., Xia, Q., Liu, K. & Dong, Z. New perspectives for targeting therapy in ALK-positive human cancers. Oncogene 42, 1959\u20131969 (2023).","journal-title":"Oncogene"},{"key":"1110_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","volume":"34","author":"SH Ou","year":"2016","unstructured":"Ou, S. H. et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J. Clin. Oncol. 34, 661\u2013668 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","volume":"17","author":"AT Shaw","year":"2016","unstructured":"Shaw, A. T. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 17, 234\u2013242 (2016).","journal-title":"Lancet Oncol."},{"key":"1110_CR37","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim, D. W. et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J. Clin. Oncol. 35, 2490\u20132498 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw, A. T. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 18, 874\u2013886 (2017).","journal-title":"Lancet Oncol."},{"key":"1110_CR39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn, L. et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 7, 1617\u20131625 (2021).","journal-title":"JAMA Oncol."},{"key":"1110_CR40","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw, A. T. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963\u20131971 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon, A. et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 261\u2013270 (2020).","journal-title":"Lancet Oncol."},{"key":"1110_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon, A. et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 390, 118\u2013131 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR43","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","volume":"43","author":"M Perol","year":"2025","unstructured":"Perol, M. et al. Taletrectinib in ROS1+ non-small cell lung cancer: trust. J. Clin. Oncol. 43, 1920\u20131929 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR44","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20, 1691\u20131701 (2019).","journal-title":"Lancet Oncol."},{"key":"1110_CR45","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","volume":"363","author":"JE Butrynski","year":"2010","unstructured":"Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727\u20131733 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388, 228\u2013239 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR47","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925\u2013935 (2023).","journal-title":"Lancet Oncol."},{"key":"1110_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"1110_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon, A. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400\u2013409 (2017).","journal-title":"Cancer Discov."},{"key":"1110_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 21, 271\u2013282 (2020).","journal-title":"Lancet Oncol."},{"key":"1110_CR51","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731\u2013739 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR52","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 23, 1261\u20131273 (2022).","journal-title":"Lancet Oncol."},{"key":"1110_CR53","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat. Med. 28, 1640\u20131645 (2022).","journal-title":"Nat. Med."},{"key":"1110_CR54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram, A. M. et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N. Engl. J. Med. 392, 566\u2013576 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn, L. B. et al. The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat. Med. 30, 207\u2013217 (2024).","journal-title":"Nat. Med."},{"key":"1110_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40478-021-01164-z","volume":"9","author":"KM Schieffer","year":"2021","unstructured":"Schieffer, K. M. et al. Molecular classification of a complex structural rearrangement of the RB1 locus in an infant with sporadic, isolated, intracranial, sellar region retinoblastoma. Acta Neuropathol. Commun. 9, 61 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1110_CR57","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-19-0127","volume":"25","author":"J Lin","year":"2019","unstructured":"Lin, J. et al. Alterations in DNA damage repair genes in primary liver cancer. Clin. Cancer Res. 25, 4701\u20134711 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR58","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/leu.2010.22","volume":"24","author":"C Haferlach","year":"2010","unstructured":"Haferlach, C. et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 24, 1065\u20131069 (2010).","journal-title":"Leukemia"},{"key":"1110_CR59","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed, R. et al. High Yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712\u20134722 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41392-025-02161-7","volume":"10","author":"SV Liu","year":"2025","unstructured":"Liu, S. V., Nagasaka, M., Atz, J., Solca, F. & Mullauer, L. Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduct. Target. Ther. 10, 111 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1110_CR61","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer v.1.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450 (2025)."},{"key":"1110_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-021-00909-y","volume":"14","author":"C Heydt","year":"2021","unstructured":"Heydt, C. et al. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Med. Genom. 14, 62 (2021).","journal-title":"BMC Med. Genom."},{"key":"1110_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-030-91836-1_9","volume":"1361","author":"DJ Hedges","year":"2022","unstructured":"Hedges, D. J. RNA-seq fusion detection in clinical oncology. Adv. Exp. Med. Biol. 1361, 163\u2013175 (2022).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1110_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000016","volume":"42","author":"EE Heyer","year":"2020","unstructured":"Heyer, E. E. & Blackburn, J. Sequencing strategies for fusion gene detection. BioEssays 42, e2000016 (2020).","journal-title":"BioEssays"},{"key":"1110_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.892918","volume":"12","author":"S An","year":"2022","unstructured":"An, S. et al. Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing. Front. Oncol. 12, 892918 (2022).","journal-title":"Front. Oncol."},{"key":"1110_CR66","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479\u20131484 (2014).","journal-title":"Nat. Med."},{"key":"1110_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41215-z","volume":"9","author":"Q Peng","year":"2019","unstructured":"Peng, Q. et al. Targeted single primer enrichment sequencing with single end duplex-UMI. Sci. Rep. 9, 4810 (2019).","journal-title":"Sci. Rep."},{"key":"1110_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cancergen.2020.02.007","volume":"243","author":"X Qu","year":"2020","unstructured":"Qu, X., Yeung, C., Coleman, I., Nelson, P. S. & Fang, M. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. Cancer Genet. 243, 11\u201318 (2020).","journal-title":"Cancer Genet."},{"key":"1110_CR69","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in Leukemia study group. J. Clin. Oncol. 28, 2529\u20132537 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1535-6108(02)00181-2","volume":"2","author":"LD Miller","year":"2002","unstructured":"Miller, L. D. et al. Optimal gene expression analysis by microarrays. Cancer Cell 2, 353\u2013361 (2002).","journal-title":"Cancer Cell"},{"key":"1110_CR71","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1001\/jama.286.18.2280","volume":"286","author":"HC King","year":"2001","unstructured":"King, H. C. & Sinha, A. A. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 286, 2280\u20132288 (2001).","journal-title":"JAMA"},{"key":"1110_CR72","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0014-5793(00)01771-3","volume":"480","author":"JE Celis","year":"2000","unstructured":"Celis, J. E. et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. 480, 2\u201316 (2000).","journal-title":"FEBS Lett."},{"key":"1110_CR73","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.drudis.2015.05.013","volume":"20","author":"A Johnson","year":"2015","unstructured":"Johnson, A. et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov. Today 20, 1433\u20131438 (2015).","journal-title":"Drug Discov. Today"},{"key":"1110_CR74","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1158\/0008-5472.CAN-17-0341","volume":"77","author":"KC Kurnit","year":"2017","unstructured":"Kurnit, K. C. et al. Personalized Cancer Therapy: a publicly available precision oncology resource. Cancer Res. 77, e123\u2013e126 (2017).","journal-title":"Cancer Res."},{"key":"1110_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini, F. et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat. Rev. 84, 101965 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"1110_CR76","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3390\/cancers12071902","volume":"12","author":"G Griguolo","year":"2020","unstructured":"Griguolo, G. et al. ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Cancers 12, 1902 (2020).","journal-title":"Cancers"},{"key":"1110_CR77","doi-asserted-by":"publisher","first-page":"21046","DOI":"10.1073\/pnas.1218750110","volume":"109","author":"SQ Ashraf","year":"2012","unstructured":"Ashraf, S. Q. et al. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc. Natl Acad. Sci. USA 109, 21046\u201321051 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1110_CR78","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.3390\/cancers14225650","volume":"14","author":"T Triulzi","year":"2022","unstructured":"Triulzi, T. et al. HER2 mRNA Levels, estrogen receptor activity and susceptibility to trastuzumab in primary breast cancer. Cancers 14, 5650 (2022).","journal-title":"Cancers"},{"key":"1110_CR79","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41416-020-01257-x","volume":"124","author":"NT Conlon","year":"2021","unstructured":"Conlon, N. T. et al. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. Br. J. Cancer 124, 1249\u20131259 (2021).","journal-title":"Br. J. Cancer"},{"key":"1110_CR80","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751\u2013758 (2019).","journal-title":"Nat. Med."},{"key":"1110_CR81","unstructured":"HCA. Human Cell Atlas. https:\/\/www.humancellatlas.org\/ (2025)."},{"key":"1110_CR82","first-page":"A163","volume":"11","author":"V Kushnarev","year":"2023","unstructured":"Kushnarev, V. et al. 143 Correlating RNA-seq detection and IHC staining of potential antibody\u2013drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLR. J. Immunother. Cancer 11, A163 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1110_CR83","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/biomedicines8050114","volume":"8","author":"M Sorokin","year":"2020","unstructured":"Sorokin, M. et al. RNA sequencing in comparison to immunohistochemistry for measuring cancer biomarkers in breast cancer and lung cancer specimens. Biomedicines 8, 114 (2020).","journal-title":"Biomedicines"},{"key":"1110_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113379","volume":"195","author":"C Bosi","year":"2023","unstructured":"Bosi, C. et al. Pan-cancer analysis of antibody\u2013drug conjugate targets and putative predictors of treatment response. Eur. J. Cancer 195, 113379 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1110_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0893-x","volume":"14","author":"LF Gulyaeva","year":"2016","unstructured":"Gulyaeva, L. F. & Kushlinskiy, N. E. Regulatory mechanisms of microRNA expression. J. Transl. Med. 14, 143 (2016).","journal-title":"J. Transl. Med."},{"key":"1110_CR86","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms21051723","volume":"21","author":"Z Ali Syeda","year":"2020","unstructured":"Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M. & Song, S. J. Regulatory mechanism of microRNA expression in cancer. Int. J. Mol. Sci. 21, 1723 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1110_CR87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtn.2022.12.016","volume":"31","author":"GL Gregory","year":"2023","unstructured":"Gregory, G. L. & Copple, I. M. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Mol. Ther. Nucleic Acids 31, 211\u2013223 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1110_CR88","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.gendis.2022.12.015","volume":"10","author":"A Ertay","year":"2023","unstructured":"Ertay, A., Ewing, R. M. & Wang, Y. Synthetic lethal approaches to target cancers with loss of PTEN function. Genes Dis. 10, 2511\u20132527 (2023).","journal-title":"Genes Dis."},{"key":"1110_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1133472","volume":"11","author":"A Ragupathi","year":"2023","unstructured":"Ragupathi, A., Singh, M., Perez, A. M. & Zhang, D. Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights. Front. Cell Dev. Biol. 11, 1133472 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"1110_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-4022-x","volume":"18","author":"Y Guo","year":"2017","unstructured":"Guo, Y., Zhao, S., Sheng, Q., Samuels, D. C. & Shyr, Y. The discrepancy among single nucleotide variants detected by DNA and RNA high throughput sequencing data. BMC Genom. 18, 690 (2017).","journal-title":"BMC Genom."},{"key":"1110_CR91","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s42003-024-06326-y","volume":"7","author":"G Tang","year":"2024","unstructured":"Tang, G. et al. Pan-cancer discovery of somatic mutations from RNA sequencing data. Commun. Biol. 7, 619 (2024).","journal-title":"Commun. Biol."},{"key":"1110_CR92","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djz114","volume":"111","author":"VTG Lin","year":"2019","unstructured":"Lin, V. T. G. & Yang, E. S. The pros and cons of incorporating transcriptomics in the age of precision oncology. J. Natl Cancer Inst. 111, 1016\u20131022 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1110_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00157-4","volume":"5","author":"E Merry","year":"2021","unstructured":"Merry, E., Thway, K., Jones, R. L. & Huang, P. H. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. npj Precis. Oncol. 5, 17 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1110_CR94","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/s41374-020-0413-8","volume":"100","author":"E Schaafsma","year":"2020","unstructured":"Schaafsma, E. et al. Whole transcriptome signature for prognostic prediction (WTSPP): application of whole transcriptome signature for prognostic prediction in cancer. Lab Invest. 100, 1356\u20131366 (2020).","journal-title":"Lab Invest."},{"key":"1110_CR95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J. Clin. Oncol. 31, 217\u2013223 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR96","doi-asserted-by":"publisher","first-page":"S712","DOI":"10.1016\/j.annonc.2023.09.2298","volume":"34","author":"Z Luo","year":"2023","unstructured":"Luo, Z. et al. 1208MO a randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary. Ann. Oncol. 34, S712 (2023).","journal-title":"Ann. Oncol."},{"key":"1110_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-020-03655-7","volume":"21","author":"J Theilhaber","year":"2020","unstructured":"Theilhaber, J., Chiron, M., Dreymann, J., Bergstrom, D. & Pollard, J. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials. BMC Bioinform. 21, 333 (2020).","journal-title":"BMC Bioinform."},{"key":"1110_CR98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2020.09.007","volume":"84","author":"AM Tsimberidou","year":"2022","unstructured":"Tsimberidou, A. M., Fountzilas, E., Bleris, L. & Kurzrock, R. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. Semin. Cancer Biol. 84, 50\u201359 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1110_CR99","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","volume":"25","author":"RA Vince Jr","year":"2022","unstructured":"Vince, R. A. Jr et al. Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis. 25, 677\u2013683 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1110_CR100","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","volume":"153","author":"KN Patel","year":"2018","unstructured":"Patel, K. N. et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 153, 817\u2013824 (2018).","journal-title":"JAMA Surg."},{"key":"1110_CR101","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1089\/thy.2022.0124","volume":"32","author":"SD Finkelstein","year":"2022","unstructured":"Finkelstein, S. D. et al. A retrospective evaluation of the diagnostic performance of an interdependent pairwise microRNA expression analysis with a mutation panel in indeterminate thyroid nodules. Thyroid 32, 1362\u20131371 (2022).","journal-title":"Thyroid"},{"key":"1110_CR102","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1097\/SLA.0000000000005904","volume":"278","author":"MN Nikiforova","year":"2023","unstructured":"Nikiforova, M. N. et al. A combined DNA\/RNA-based next-generation sequencing platform to improve the classification of pancreatic cysts and early detection of pancreatic cancer arising from pancreatic cysts. Ann. Surg. 278, e789\u2013e797 (2023).","journal-title":"Ann. Surg."},{"key":"1110_CR103","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"1110_CR104","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdz052","volume":"30","author":"E Fontana","year":"2019","unstructured":"Fontana, E., Eason, K., Cervantes, A., Salazar, R. & Sadanandam, A. Context matters \u2014 consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann. Oncol. 30, 520\u2013527 (2019).","journal-title":"Ann. Oncol."},{"key":"1110_CR105","unstructured":"Stahler, A. et al. ASCO Vol. 42 (Journal of Clinical Oncology, 2024)."},{"key":"1110_CR106","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay, C. M. et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39, 346\u2013360.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1110_CR107","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1110_CR108","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","volume":"184","author":"JS Lee","year":"2021","unstructured":"Lee, J. S. et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 184, 2487\u20132502.e13 (2021).","journal-title":"Cell"},{"key":"1110_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17678-4","volume":"11","author":"B Schmauch","year":"2020","unstructured":"Schmauch, B. et al. A deep learning model to predict RNA-seq expression of tumours from whole slide images. Nat. Commun. 11, 3877 (2020).","journal-title":"Nat. Commun."},{"key":"1110_CR110","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s43018-024-00793-2","volume":"5","author":"DT Hoang","year":"2024","unstructured":"Hoang, D. T. et al. A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics. Nat. Cancer 5, 1305\u20131317 (2024).","journal-title":"Nat. Cancer"},{"key":"1110_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301100","volume":"14","author":"RK Shah","year":"2023","unstructured":"Shah, R. K., Cygan, E., Kozlik, T., Colina, A. & Zamora, A. E. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy. Front. Immunol. 14, 1301100 (2023).","journal-title":"Front. Immunol."},{"key":"1110_CR112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1110_CR113","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/lary.30761","volume":"134","author":"LGT Morris","year":"2024","unstructured":"Morris, L. G. T. Loss of human leukocyte antigen and immune escape in head and neck cancer. Laryngoscope 134, 160\u2013165 (2024).","journal-title":"Laryngoscope"},{"key":"1110_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509","volume":"16","author":"X Han","year":"2025","unstructured":"Han, X. et al. The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies. Front. Immunol. 16, 1512509 (2025).","journal-title":"Front. Immunol."},{"key":"1110_CR115","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schrors, B., Lower, M., Tureci, O. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1110_CR116","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-20-4314","volume":"27","author":"CW Abbott","year":"2021","unstructured":"Abbott, C. W. et al. Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms. Clin. Cancer Res. 27, 4265\u20134276 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR117","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jtho.2019.06.016","volume":"14","author":"YK Chae","year":"2019","unstructured":"Chae, Y. K. et al. Clinical and immunological implications of frameshift mutations in lung cancer. J. Thorac. Oncol. 14, 1807\u20131817 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1110_CR118","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","volume":"3","author":"L Scheetz","year":"2019","unstructured":"Scheetz, L. et al. Engineering patient-specific cancer immunotherapies. Nat. Biomed. Eng. 3, 768\u2013782 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"1110_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1251603","volume":"14","author":"BQT Nguyen","year":"2023","unstructured":"Nguyen, B. Q. T. et al. Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling. Front. Immunol. 14, 1251603 (2023).","journal-title":"Front. Immunol."},{"key":"1110_CR120","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm6359","volume":"8","author":"A Merlotti","year":"2023","unstructured":"Merlotti, A. et al. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci. Immunol. 8, eabm6359 (2023).","journal-title":"Sci. Immunol."},{"key":"1110_CR121","doi-asserted-by":"publisher","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1110_CR122","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.3390\/cancers12102879","volume":"12","author":"AV Gopanenko","year":"2020","unstructured":"Gopanenko, A. V., Kosobokova, E. N. & Kosorukov, V. S. Main strategies for the identification of neoantigens. Cancers 12, 2879 (2020).","journal-title":"Cancers"},{"key":"1110_CR123","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg3778","volume":"15","author":"XD Fu","year":"2014","unstructured":"Fu, X. D. & Ares, M. Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 15, 689\u2013701 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"1110_CR124","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00439-017-1790-y","volume":"136","author":"LM Gallego-Paez","year":"2017","unstructured":"Gallego-Paez, L. M. et al. Alternative splicing: the pledge, the turn, and the prestige: the key role of alternative splicing in human biological systems. Hum. Genet. 136, 1015\u20131042 (2017).","journal-title":"Hum. Genet."},{"key":"1110_CR125","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal, S. C., Lopez-Oreja, I. & Valcarcel, J. Roles and mechanisms of alternative splicing in cancer \u2014 implications for care. Nat. Rev. Clin. Oncol. 17, 457\u2013474 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1110_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1110_CR127","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton, G. M. et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 5, 850\u2013859 (2015).","journal-title":"Cancer Discov."},{"key":"1110_CR128","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf, J. et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N. Engl. J. Med. 383, 944\u2013957 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR129","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik, P. K. et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N. Engl. J. Med. 383, 931\u2013943 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR130","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1110_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8103","volume":"6","author":"M Salton","year":"2015","unstructured":"Salton, M. et al. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat. Commun. 6, 7103 (2015).","journal-title":"Nat. Commun."},{"key":"1110_CR132","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282\u2013296.e4 (2018).","journal-title":"Cell Rep."},{"key":"1110_CR133","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/or.2023.8664","volume":"51","author":"Q Nian","year":"2024","unstructured":"Nian, Q. et al. U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review). Oncol. Rep. 51, 5 (2024).","journal-title":"Oncol. Rep."},{"key":"1110_CR134","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith, M. A. et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat. Cell Biol. 21, 640\u2013650 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1110_CR135","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","volume":"26","author":"LH Gallo","year":"2015","unstructured":"Gallo, L. H., Nelson, K. N., Meyer, A. N. & Donoghue, D. J. Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 26, 425\u2013449 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1110_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84107-x","volume":"11","author":"M Yashiro","year":"2021","unstructured":"Yashiro, M. et al. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci. Rep. 11, 4698 (2021).","journal-title":"Sci. Rep."},{"key":"1110_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1736","volume":"14","author":"M Katoh","year":"2024","unstructured":"Katoh, M., Nakayama, I., Wainberg, Z. A., Shitara, K. & Katoh, M. Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours. Clin. Transl. Med. 14, e1736 (2024).","journal-title":"Clin. Transl. Med."},{"key":"1110_CR138","volume":"16","author":"A Samanta","year":"2024","unstructured":"Samanta, A., Ghosh, A. & Sarma, M. Zolbetuximab for unresectable and metastatic gastric and gastroesophageal junction adenocarcinoma: a review of literature. Cureus 16, e75206 (2024).","journal-title":"Cureus"},{"key":"1110_CR139","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/humu.24212","volume":"42","author":"TV Riepe","year":"2021","unstructured":"Riepe, T. V., Khan, M., Roosing, S., Cremers, F. P. M. & t Hoen, P. A. C. Benchmarking deep learning splice prediction tools using functional splice assays. Hum. Mutat. 42, 799\u2013810 (2021).","journal-title":"Hum. Mutat."},{"key":"1110_CR140","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13900","volume":"2","author":"R Karam","year":"2019","unstructured":"Karam, R. et al. Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. JAMA Netw. Open 2, e1913900 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1110_CR141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007231","volume":"14","author":"CL Rhine","year":"2018","unstructured":"Rhine, C. L. et al. Hereditary cancer genes are highly susceptible to splicing mutations. PLoS Genet. 14, e1007231 (2018).","journal-title":"PLoS Genet."},{"key":"1110_CR142","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jmoldx.2022.12.002","volume":"25","author":"N Kamps-Hughes","year":"2023","unstructured":"Kamps-Hughes, N. et al. A systematic method for detecting abnormal mRNA splicing and assessing its clinical impact in individuals undergoing genetic testing for hereditary cancer syndromes. J. Mol. Diagn. 25, 156\u2013167 (2023).","journal-title":"J. Mol. Diagn."},{"key":"1110_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0109-y","volume":"4","author":"T Landrith","year":"2020","unstructured":"Landrith, T. et al. Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. npj Precis. Oncol. 4, 4 (2020).","journal-title":"npj Precis. Oncol."},{"key":"1110_CR144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41525-022-00323-y","volume":"7","author":"C Horton","year":"2022","unstructured":"Horton, C. et al. Mutational and splicing landscape in a cohort of 43,000 patients tested for hereditary cancer. npj Genom. Med. 7, 49 (2022).","journal-title":"npj Genom. Med."},{"key":"1110_CR145","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","volume":"14","author":"KD Davies","year":"2019","unstructured":"Davies, K. D. et al. DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. J. Thorac. Oncol. 14, 737\u2013741 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1110_CR146","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","volume":"36","author":"L Belcaid","year":"2025","unstructured":"Belcaid, L. et al. Copenhagen Prospective Personalized Oncology (CoPPO) \u2014 impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting. Ann. Oncol. 36, 1078\u20131087 (2025).","journal-title":"Ann. Oncol."},{"key":"1110_CR147","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.annonc.2022.05.522","volume":"33","author":"E Pleasance","year":"2022","unstructured":"Pleasance, E. et al. Whole-genome and transcriptome analysis enhances precision cancer treatment options. Ann. Oncol. 33, 939\u2013949 (2022).","journal-title":"Ann. Oncol."},{"key":"1110_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.261","volume":"4","author":"Q Zhong","year":"2023","unstructured":"Zhong, Q. et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm 4, e261 (2023).","journal-title":"MedComm"},{"key":"1110_CR149","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41571-020-00449-x","volume":"18","author":"SH Gohil","year":"2021","unstructured":"Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B. & Livak, K. J. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 244\u2013256 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1110_CR150","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-024-07935-7","volume":"633","author":"K Motone","year":"2024","unstructured":"Motone, K. et al. Multi-pass, single-molecule nanopore reading of long protein strands. Nature 633, 662\u2013669 (2024).","journal-title":"Nature"},{"key":"1110_CR151","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41571-018-0135-7","volume":"16","author":"B Zhang","year":"2019","unstructured":"Zhang, B. et al. Clinical potential of mass spectrometry-based proteogenomics. Nat. Rev. Clin. Oncol. 16, 256\u2013268 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1110_CR152","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n, J. et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat. Med. 30, 1645\u20131654 (2024).","journal-title":"Nat. Med."},{"key":"1110_CR153","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1200\/JCO.24.00427","volume":"42","author":"A Dilawari","year":"2024","unstructured":"Dilawari, A. et al. US Food and Drug Administration Approval Summary: capivasertib with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. J. Clin. Oncol. 42, 4103\u20134113 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR154","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.lungcan.2020.08.021","volume":"149","author":"J Li","year":"2020","unstructured":"Li, J. et al. Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing. Lung Cancer 149, 17\u201322 (2020).","journal-title":"Lung Cancer"},{"key":"1110_CR155","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1200\/JCO.2021.39.15_suppl.9021","volume":"39","author":"X Le","year":"2021","unstructured":"Le, X. et al. Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp). J. Clin. Oncol. 39, 9021\u20139021 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR156","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom, L. D. et al. MRTX1719 Is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13, 2412\u20132431 (2023).","journal-title":"Cancer Discov."},{"key":"1110_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder, M. et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat. Commun. 16, 423 (2025).","journal-title":"Nat. Commun."},{"key":"1110_CR158","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1110_CR159","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","volume":"14","author":"RM Giusti","year":"2008","unstructured":"Giusti, R. M. et al. U.S. Food and Drug Administration Approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin. Cancer Res. 14, 1296\u20131302 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR160","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035\u20134039 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR161","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","volume":"30","author":"K Natrajan","year":"2024","unstructured":"Natrajan, K., Kaushal, M., George, B., Kanapuru, B. & Theoret, M. R. FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin. Cancer Res. 30, 2865\u20132871 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1110_CR162","doi-asserted-by":"publisher","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2023-CT001","volume":"83","author":"A Khattak","year":"2023","unstructured":"Khattak, A. et al. Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201\/keynote-942 trial. Cancer Res. 83, CT001 (2023).","journal-title":"Cancer Res."},{"key":"1110_CR163","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2217\/fon-2018-0221","volume":"15","author":"M Brand\u00e3o","year":"2019","unstructured":"Brand\u00e3o, M., Pond\u00e9, N. & Piccart-Gebhart, M. Mammaprint\u2122: a comprehensive review. Future Oncol. 15, 207\u2013224 (2019).","journal-title":"Future Oncol."},{"key":"1110_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00145","volume":"2","author":"SP Thomas","year":"2018","unstructured":"Thomas, S. P. et al. Multi-institutional, prospective clinical utility study evaluating the impact of the 92-gene assay (CancerTYPE ID) on final diagnosis and treatment planning in patients with metastatic cancer with an unknown or unclear diagnosis. JCO Precis. Oncol. 2, 1\u201312 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"1110_CR165","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.21873\/anticanres.17304","volume":"44","author":"K Fujiya","year":"2024","unstructured":"Fujiya, K. et al. A gene expression signature that predicts gastric cancer sensitivity to PARP inhibitor therapy. Anticancer Res. 44, 4779\u20134788 (2024).","journal-title":"Anticancer Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01110-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:02:19Z","timestamp":1771938139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":165,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1110"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01110-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"21 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. declares research funding from Aileron Therapeutics, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech, Guardant Health, Jazz Pharmaceuticals, Klus Pharma, Novartis, Puma Biotechnology, Taiho Pharmaceutical, Takeda Pharmaceutical and Zymeworks; honoraria from Dava Oncology; consultancy\/advisory roles for AstraZeneca Pharmaceuticals, Becton Dickinson, Calibr (a division of Scripps Research), Cybrexa, Daiichi Sankyo, Dava Oncology, Debiopharm, EcoR1 Capital, eFFECTOR Therapeutics, Elevation Oncology, Exelixis, FogPharma, go Therapeutics, GT Aperion, Guardant Health, Harbinger Health, Incyte, Jazz Pharmaceuticals, Karyopharm Therapeutics, Kivu Biosciences, LegoChem Biosciences, Lengo Therapeutics, LOXO-Oncology, Menarini Group, Mersana Therapeutics, Molecular Templates, OnCusp Therapeutics, Protai Bio, Ribometrix, Sanofi Pharmaceuticals, Seagen, Tallac Therapeutics, Tempus, Theratechnologies, Zentalis Pharmaceuticals and Zymeworks; travel-related support from the Cholangiocarcinoma Foundation Dava Oncology, the European Organization for Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO); and institutional funding and technology support from Royal Philips. J.R. declares non-financial support and reasonable reimbursement for travel from 280-Biotech, the American Society of Medical Oncology (ASCO), Dava Oncology, ESMO, the National Taiwan University Cancer Center and STOP Cancer; consulting and travel fees from Aadi, Amgen, Bridgebio (including serving on scientific advisory boards) and from Ellipses Pharma, IONCTURA, Mekanistic, Merus, MonteRosa and Sardona; consulting fees from Axiom, Boxer Capital, the Chinese University of Hong Kong, Guidepoint, Tang Advisors and the Vall d\u2019Hebron Institute of Oncology; research funding from 280 Bio, AstraZeneca, Blueprint Medicines, Hummingbird, Merck Sharp & Dohme and the Vall d\u2019Hebron Institute of Oncology\/Cancer Core Europe; and serving as an investigator in clinical trials sponsored by AadiBioscience, Adcentrix, Alnylam, Alterome, Amgen, AstraZeneca, Bicycle Therapeutics, Beigene, BioAlta, BioTheryX, C4 Therapeutics, Cancer Core Europe, Debio, Exelixis, Fog Pharmaceuticals, ForeBio, FusionPharma, GlaxoSmithKline, Hotspot Pharma, Hummingbird, Hutchinson MediPharma, Ideaya, Immuneering Corp, Incyte, Kelun-Biotech, Kinnate, Linnaeus Therapeutics, LOXO-Oncology, MapKure, Merus, Mirati, MonteRosa, Novartis, Nuvectis Pharma, Pfizer, Relay, Roche Pharmaceuticals, Scorpion Therapeutics, Storm Therapeutics, Symphogen, Taiho Pharmaceutical, Tango Therapeutics, Tyra, Vividion and Yingli. S.K. is a scientific adviser for VieCure. D.H. declares serving on advisory boards for and consulting fees from AstraZeneca and Carden Jennings. A.K. declares salary support from BostonGene. F.M.-B. declares research funding from Aileron Therapeutics, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech, Guardant Health, Jazz Pharmaceuticals, Klus Pharma, Novartis, Puma Biotechnology, Takeda Pharmaceutical, Taiho Pharmaceutical and Zymeworks; honoraria from Dava Oncology; consultancy\/advisory roles for AstraZeneca, Becton Dickinson, Calibr (a division of Scripps Research), Cybrexa, Daiichi Sankyo, Dava Oncology, Debiopharm, EcoR1 Capital, eFFECTOR Therapeutics, Elevation Oncology, Exelixis, FogPharma, go Therapeutics, GT Aperion, Guardant Health, Harbinger Health, Incyte, Jazz Pharmaceuticals, Karyopharm Therapeutics, Kivu Biosciences, LegoChem Biosciences, Lengo Therapeutics, LOXO-Oncology, Menarini Group, Mersana Therapeutics, Molecular Templates, OnCusp Therapeutics, Protai Bio, Ribometrix, Sanofi Pharmaceuticals, Seagen, Theratechnologies, Tallac Therapeutics, Tempus, Zentalis Pharmaceuticals and Zymeworks; travel-related support from the Cholangiocarcinoma Foundation, Dava Oncology, EORTC and ESMO; and institutional funding and technology support from Royal Philips. The other authors declare no competing interests. MD Anderson received licensing fees for the Precision Oncology Decision Support (PODS) database from Philips Healthcare, which supported development of this system at MD Anderson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}